Evidence map›Paper›PMID 30208970›Full record

ArticleJournal of translational medicine2018

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.

Jianqun Kou, Phillip R Musich, Ben Staal, Liang Kang, Yuan Qin, Zhi Q Yao, Boheng Zhang, Weizhong Wu, Angela Tam, Alan Huang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Bispecific antibody drug conjugates: Making 1+1>2.Acta pharmaceutica Sinica. B · 2024
    Review
  7. Article
  8. Advanced Cell Therapies for Glioblastoma.Frontiers in immunology · 2022
    Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Jianqun KouDepartment of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
Phillip R MusichDepartment of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
Ben StaalCenter of Cell and Cancer Biology, Van Andel Research Institute, Grand Rapids, MI, 49503, USA.
Liang KangCenter of Cell and Cancer Biology, Van Andel Research Institute, Grand Rapids, MI, 49503, USA.
Yuan QinDepartment of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
Zhi Q YaoCenter of Excellence for Inflammation, Infectious Disease and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
Boheng ZhangLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Weizhong WuLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Angela TamNovartis Institutes for BioMedical Research, Cambridge, MA, 02139, USA.
Alan HuangNovartis Institutes for BioMedical Research, Cambridge, MA, 02139, USA.
Huai-Xiang HaoNovartis Institutes for BioMedical Research, Cambridge, MA, 02139, USA.
George F Vande WoudeCenter of Cell and Cancer Biology, Van Andel Research Institute, Grand Rapids, MI, 49503, USA.
Qian XieDepartment of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA. xieq01@etsu.edu.ORCID 0000-0003-4206-1736
East Tennessee State University · USNovartis (United States) · USVan Andel Institute · USFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAberrant MET tyrosine kinase signaling is known to cause cancer initiation and progression. While MET inhibitors are in clinical trials against several cancer types, the clinical efficacies are controversial and the molecular mechanisms toward sensitivity remain elusive.

methodsWith the goal to investigate the molecular basis of MET amplification (MET

resultsWe find that cancer cells driven by MET

conclusionsOur results demonstrate that MET

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAtaxia Telangiectasia Mutated ProteinsAutocrine CommunicationBenzamidesCell Cycle CheckpointsCell Line, TumorCell ProliferationDNA Breaks, Double-StrandedDNA RepairHepatocyte Growth FactorHumansHuman Umbilical Vein Endothelial CellsImidazolesMice, SCIDAntibodies, MonoclonalAntibodies, NeutralizingAtaxia Telangiectasia Mutated ProteinsATM protein, humanBenzamidescapmatinibHepatocyte Growth FactorHGF protein, humanImidazolesonartuzumabProtein Kinase InhibitorsProto-Oncogene Proteins c-metTP53BP1 protein, humanTriazinesTumor Suppressor p53-Binding Protein 1Combination therapyHepatocyte growth factorMetNeutralizing antibodyTargeted therapyTyrosine kinase inhibitor

Identifiers

PMID30208970
PMCPMC6134500
OpenAlexW2890522709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.